14, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug ... agreed to sell an aggregate of 15,312,500 shares of its common stock and warrants to purchase up to …
Generex Biotechnology (GNBT) describes itself as "the leader in drug delivery ... That’s right,"could result" in 2013. The stock moved up 42% to $1.79. For the present, the company had $45,000 in revenue in the last reported quarter.
Generex Biotechnology (GNBT) just announced a few minutes ago that results from ... Generex Biotechnology has since broken out of its narrow trading range and is now up 0.11 at $0.43. The stock is attempting to rebound from the lows of …
Generex Biotechnology Corp. (OTCQB:GNBT - News) stock volume soared Mar. 11, with 9,325,106 shares changing hands, significantly higher than its three-month average volume of 7,012,285 shares. This surge in volume comes on the …
Shares of Generex Biotechnology (PINK:GNBT) have lost a whopping 74% so far this year, sending shares to a 52-week low of under 4 cents. The company shed nearly 10% in one day late last month after announcing a secondary stock
Antigen Express, Inc., a wholly-owned subsidiary of Generex Biotechnology Corporation (GNBT) Antigen Express is advancing its ... MD Becker Partners receives no compensation to write about any specific stock, sector or theme, and …
(Comment on this article at http://www.financialwire.net/2010/04/21/insurance-in-focus-generex-establishes-reimbursement-plan-for-oral-lyn/) April 21, 2010 (FinancialWire) -- Generex Biotechnology Corp. (NASDAQ: GNBT) …
Since February 2017, Dr. Terrell has also concurrently served as both a director and Chief Medical Diagnostics Officer of Generex Biotechnology Corporation (OTCMKTS: GNBT), a publicly-held biopharmaceutical company focused on …
Generex Biotechnology Corporation (Nasdaq: GNBT) announced today publication of results from the first Phase I study of its lead immunotherapeutic agent AE37 in patients with prostate cancer. At the end of 2009, the Company announced …
Oral-lyn is an oral insulin product that is developed by Generex Biotechnology Corp. (GNBT). Oral-lyn is presently approved ... In April 2008, MannKind stock was hit hard following uncertainty about the inhaled insulin treatment due to the …